Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Phibro Animal Health (PAHC): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow PAHC for free
Share

Sections with a free account

No concentrated manager holds it. 1 officer or director bought in 6 months.

Who owns Phibro Animal Health?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the Class A shares: BFI (13D/A filed May 22, 2026), BlackRock (13G/A filed Apr 28, 2025), FMR (13G/A filed Aug 6, 2026) and Vanguard Capital Management (13G filed Apr 30, 2026). Bendheim Jack is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders of Class A reported on Form 13F were BlackRock (15.3% of Class A), FMR (15.0%) and State Street (4.9%).

Which institutions hold the most Phibro Animal Health shares?

Per Form 13F filings as of Jun 30, 2026, as a share of Class A:

  1. 1. BlackRock: 15.3%
  2. 2. FMR: 15.0%
  3. 3. State Street: 4.9%
  4. 4. Millennium Management: 4.4%
  5. 5. Vanguard Capital Management: 4.4%
  6. 6. Geode Capital Management: 3.1%
  7. 7. Lord, Abbett: 3.1%
  8. 8. Dimensional Fund Advisors: 2.5%
  9. 9. Vanguard Portfolio Management: 2.4%
  10. 10. Renaissance Technologies: 2.3%

How much of Phibro Animal Health do institutions own?

The 210 institutions that file 13F reported 99.7% of the Class A shares as of Jun 30, 2026.

Sources:13D/A by BFI (May 22, 2026) ↗13G/A by BlackRock (Apr 28, 2025) ↗13G/A by FMR (Aug 6, 2026) ↗13G by Vanguard Capital Management (Apr 30, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the Class A shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. With more than one share class, a 13D or 13G counts shares convertible from another class as owned, so we do not show its percentage. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Phibro Animal Health revenue

Phibro Animal Health reported annual revenue of $1.52 billion for fiscal year 2026 (year ended June 30, 2026), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
—
All 13F: 210
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$31.4
-43.2% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Concentrated managers holding it

None in the latest quarter.

Largest holders of PAHC (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Sep 30, 2026 · balance sheet as of Sep 30, 2026.

Profitability
Operating margin
12.5%
Net margin
6.7%
ROE
24.6%
Growth
Revenue (TTM)
$1.5 bn
Revenue growth
10.1%
Net income (TTM)
$103M
Balance sheet
Net debt / EBITDA
2.2x
Free cash flow (TTM)
$21.7M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2026: 41.0 M

41.0 M0
20172026

There is a jump that may be an undetected split: we do not show the changes.

Buybacks (FY 2026)
no data
Share issuance
no data
Stock-based compensation
$1.6M0.1% of revenue
Dividends paid
$19.5M

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
0.83
Interest coverage (operating income ÷ interest)
4.2 timesfiscal 2026
Debt due within 12 months
$25.0M0.30 times cash and investments

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
1
Amount (6 m)
$318K
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Jun 26, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Apr 14, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Dec 18, 2025Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «Phibro Animal Health Corporation Announces Leadership Transition - Jack Bendheim to assume the role of Executive Chairman; Daniel Bendheim named Chief…»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow PAHC for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow PAHC